Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency.
BACKGROUND
Contrast-induced nephropathy (CIN) is known to increase morbidity and mortality of cardiovascular disease. Recent studies have shown statins prevented CIN after contrast media exposure, but optimal statin type and dosage are still unknown.


OBJECTIVE
The aims of the present study were to evaluate whether chronic pravastatin treatment before scheduled coronary angiography or percutaneous coronary intervention could reduce the incidence of CIN and to elucidate the factors related to CIN in patients with renal insufficiency.


METHODS
We studied 431 consecutive patients with renal insufficiency. One hundred ninety-four patients were receiving pravastatin treatment as standard chronic treatment of hypercholesterolemia. Serum creatinine levels were measured at baseline (pre-procedure) and within 48 h after contrast media exposure (peak post-procedure). CIN was defined as an increase in the serum creatinine values of > or = 25% or > or = 0.5 mg/dl after contrast media exposure. Logistic regression analysis was performed to evaluate the important factors related to CIN using four variables: age, pravastatin, pre-procedure serum creatinine, and contrast volume.


RESULTS
CIN was observed in 36 patients (8.4%). Patients without pravastatin (p<0.01), high level pre-procedure serum creatinine (p<0.01), and high contrast volume (p=0.034) had a significantly higher incidence of CIN. Logistic regression analysis revealed that pravastatin treatment (chi(2)=6.549, p=0.011, odds ratio=0.34), pre-procedure serum creatinine (chi(2)=6.294, p=0.009, odds ratio=2.78), and contrast volume (chi(2)=4.484, p=0.034, odds ratio=1.01) were independently related to the decreased risk of CIN.


CONCLUSIONS
Chronic pravastatin treatment before contrast media exposure was important for preventing CIN in patients with renal insufficiency. Also, reducing the dose of contrast media was important for preventing CIN in patients with high-baseline serum creatinine levels.
Yoshida
Susumu
S
The Cardiovascular Center, Kansai Medical University, 2-3-1 Shinmachi, Hirakata, Osaka 573-1191, Japan. yoshidas@hirakata.kmu.ac.jp
Kamihata
Hiroshi
H
Nakamura
Seishi
S
Senoo
Takeshi
T
Manabe
Kenichi
K
Motohiro
Masayuki
M
Sugiura
Tetsuro
T
Iwasaka
Toshiji
T
D000368:Aged; D017130:Angioplasty; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000150:complications; D003287:Contrast Media / Q000009:adverse effects*; D017023:Coronary Angiography; D003404:Creatinine / Q000097:blood; D003920:Diabetes Mellitus; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000008:administration & dosage*; D051437:Renal Insufficiency / Q000150:complications; D012307:Risk Factors
D015415:Biomarkers; D003287:Contrast Media; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D003404:Creatinine; D017035:Pravastatin